In 2000 the American Thoracic Society (ATS) and European Respiratory Society (ERS) published an international consensus statement with guidelines for the diagnosis and treatment of IPF [4
]. This recommended that patients with IPF should be treated with a combined therapy of corticosteroids and an immunosuppressive agent (e.g. azathioprine or cyclophosphamide) until adequate studies had been performed to define the best treatment for IPF. Three years later, we conducted a Cochrane review of the use of corticosteroids in IPF [5
]. This analysis showed that there were no existing placebo-controlled clinical trials that had assessed the efficacy of corticosteroid therapy in IPF patients. Therefore, no existing evidence supported the efficacy of corticosteroids for in the treatment of IPF patients.
We then did the same review on the use of immunomodulatory agents in IPF in 2003 [6
]. Four randomised, controlled clinical studies were suitable for a meta-analysis [7
]; however, these studies used four different immunosuppressive agents (cyclophosphamide, azathioprine, colchicine and interferon gamma-1b) and so a meta-analysis was not possible. The authors concluded that there was little evidence to justify the routine use of any immunosuppressive agent (or in fact any non-corticosteroid agent) in the management of IPF at that time.
In 2010, the Cochrane meta-analysis on the use of corticosteroids for IPF was updated [11
]. However, seven years after the publication of the first Cochrane review on the use of corticosteroids in IPF, there was still no evidence to support the efficacy of corticosteroids in the management of IPF, but there was also no evidence to rule out the use of corticosteroids in IPF [11
]. Therefore clinicians were left with continued uncertainty over the use of these agents in IPF. Since 2003, no placebo-controlled trials of corticosteroids in IPF had been undertaken, probably due to the fact that there was simply no previous clear evidence to show that they were, or were not, an effective treatment option. However, the recent PANTHER-IPF Study has suggested that there was an increased risk of death and hospitalizations in patients with IPF who were treated with a combination of prednisone, azathioprine, and NAC, as compared with placebo [12
In 2010, a systematic search was conducted to identify RCT that investigated the use of non-steroid agents for the treatment of IPF. This then became the subject of a further Cochrane Review [13
]. This systematic search found that, in 2010, thirteen RCT could be included. Contact with pharmaceutical companies and fellow researchers led to the identification of two other suitable clinical trials which would have been published soon after the timing of the analysis, allowing their inclusion. The analysis of endpoints and quality of the methodology of these fifteen trials reduced the number to seven that were eligible for meta-analyses: only the antifibrotic agents interferon gamma-1b and pirfenidone were evaluated in more than one trial and, therefore, were potentially eligible for two separate meta-analyses.
Combining the data from the two RCT on interferon gamma-1b [14
] in a meta-analysis, using the clinical endpoint of overall survival, showed that there were no statistically significant differences in mortality between interferon gamma-1b and placebo. Interestingly, the larger of the two trials, published by King et al., was negative for efficacy in terms of the overall survival endpoint [14
], whereas the smaller trial almost demonstrated statistical significance [15
For the treatment effect of pirfenidone, the three clinical trials that were eligible for analysis, i.e. the two large, international, randomized CAPACITY (004 and 006) trials [16
] and the Japanese SP3 trial,[17
] did not have a common primary endpoint (FVC and VC, respectively). However, the identification of data for inclusion in a specific Cochrane meta-analysis is based on pre-defined criteria. Progression-free survival (PFS) data, defined as either death or 10% decrease in FVC, was used as a secondary endpoint in the CAPACITY studies and the Japanese study published by Taniguchi et al.[17
] Definitive evidence of clinical efficacy in a Phase 3 trial is best shown by a beneficial impact on a clinically meaningful endpoint—that is, an endpoint that directly measures how a patient feels (symptoms), functions (the ability to perform activities in daily life), or survives. For patients with IPF, there are currently no validated surrogate endpoints [18
]. Nevertheless, PFS data from these studies were considered suitable for a meta-analysis based on these criteria. The overall result of this meta-analysis showed that treatment with pirfenidone reduced the risk of disease progression by 30% (HR 0.70, 95% CI 0.56 to 0.88; Figure ) [13
]. This highlights that pirfenidone is the only drug to date that has shown a significant effect on progression free survival, defined as either death or 10% FVC decrease, compared with placebo in patients with IPF.
Figure 1 Meta-analysis of progression-free survival with pirfenidone in IPF (Adapted from: 1. Spagnolo P, Del Giovane C, Luppi F, et al. Cochrane Database Syst Rev 2010, 9:CD003134. 2. Noble PW, Albera C, Bradford WZ, et al. Lancet 2011, 377:1760-1769. 3. Taniguchi (more ...)
The number of clinical trials investigating treatments for IPF is expected to continue to increase, and the use of multiple different drugs in the treatment of IPF might be observed in the future. There are multiple on-going trials investigating potential therapeutic agents acting on various different targets. This is very encouraging for IPF patients and doctors, in terms of the research effort focused on finding a suitable treatment.